Neuroprotection of Maslinic Acid, a Novel Glycogen Phos-phorylase Inhibitor, in Type 2 Diabetic Rats

Teng GUAN,Yi-Song QIAN,Meng-Hao HUANG,Long-Fei HUANG,Xu-Zhen TANG,Yun-Man LI,Hong-Bin SUN
DOI: https://doi.org/10.1016/s1875-5364(10)60037-4
IF: 3.887
2010-01-01
Chinese Journal of Natural Medicines
Abstract:AIM:To investigate the effects of maslinic acid(MA),a novel glycogen phosphorylase inhibitor in hyperglycemic rats after cerebral ischemia/reperfusion injury.METHODS:Rats were fed with high fat diet(HFD)followed by low-dose streptozotocin(STZ)injection to induce metabolic syndrome.Three doses of MA(10,5 and 2.5 mg-kg-1.d-1)were administered once daily by i.g.for2 weeks.Neurological outcomes were compared in vehicle and MA treated HFD/STZ rats with cerebral ischemia/reperfusion injury induced by bilateral common carotid artery occlusion.RESULTS:The elevation of plasma fasting glucose(GLU),serum plasma triglyceride(TG)and plasma total cholesterol(TC)was antagonized by MA significantly.Cerobral ischemia with pre-existing hyperglycemia and hyperlipemia caused prominent elevation in MDA levels and decrease in SOD activity.Extensive neuronal death occurred in the CA1 area of hippocampus at day 3 after forobrain ischemia.MA significantly attenuated ischemia-induced neuronal death in a dose-dependent manner.Moreover,MA caused a significant reduction in MDA levels and elevation in SOD activity in both cortex and hippocampus.CONCLUSION:Results suggested the prophylaxis of MA may also show beneficial effects in reducing cerebral damage after stroke for patients with type 2 diabetes.
What problem does this paper attempt to address?